



(12) Translation of
European patent specification

(11) NO/EP 3448859 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 487/04 (2006.01)
A61K 31/407 (2006.01)
A61P 7/00 (2006.01)
C07D 519/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.11.04
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.07.10
(86)	European Application Nr.	18716455.3
(86)	European Filing Date	2018.03.20
(87)	The European Application's Publication Date	2019.03.06
(30)	Priority	2017.03.20, US, 201762473751 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated Validation States:	KH; MA; MD; TN
(73)	Proprietor	Forma Therapeutics, Inc., 500 Arsenal St., Suite 100, Watertown, MA 02472, USA
(72)	Inventor	ERICSSON, Anna, c/o Forma Therapeutics Inc.500 Arsenal StreetSuite 100, Watertown, Massachusetts 02472, USA GREEN, Neal, c/o Forma Therapeutics Inc.500 Arsenal StreetSuite 100, Watertown, Massachusetts 02472, USA GUSTAFSON, Gary, c/o Forma Therapeutics Inc.500 Arsenal StreetSuite 100, Watertown, Massachusetts 02472, USA HAN, Bingsong, c/o Forma Therapeutics Inc.500 Arsenal StreetSuite 100, Watertown, Massachusetts 02472, USA LANCIA, JR., David R., c/o Forma Therapeutics Inc.500 Arsenal StreetSuite 100, Watertown, Massachusetts 02472, USA MITCHELL, Lorna, c/o Forma Therapeutics Inc.500 Arsenal StreetSuite 100, Watertown, Massachusetts 02472, USA RICHARD, David, c/o Forma Therapeutics Inc.500 Arsenal StreetSuite 100, Watertown, Massachusetts 02472, USA SHELEKHIN, Tatiana, c/o Forma Therapeutics Inc.500 Arsenal StreetSuite 100, Watertown, Massachusetts 02472, USA SMITH, Chase C., c/o Forma Therapeutics Inc.500 Arsenal StreetSuite 100, Watertown, Massachusetts 02472, USA WANG, Zhongguo, c/o Forma Therapeutics Inc.500 Arsenal StreetSuite 100, Watertown, Massachusetts 02472, USA

ZHENG, Xiaozhang, c/o Forma Therapeutics Inc.500 Arsenal StreetSuite 100,
Watertown, Massachusetts 02472, USA

(74) Agent or Attorney OSLO PATENTKONTOR AS, Hoffsvæien 1A, 0275 OSLO, Norge

(54) Title **PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS**







(56) References






Cited: WO-A1-2012/151450
WO-A1-2014/139144
WO-A1-2010/028761
WO-A1-2014/061031

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse valgt fra gruppen bestående av:

Eksempel	Struktur	Navn
1		(S)-1-(5-((2,3-dihydro[1,4]dioksino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-fenylpropan-1-on
3		(R)-1-(5-((2,3-dihydro[1,4]dioksino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-(pyridin-2-yl)propan-1-on
26		(2S,3R og 2R,3S)-1-(5-((4-(difluormetoksy)fenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-fenylbutan-1-on
27		(2R,3R og 2S,3S)-1-(5-((4-(difluormetoksy)fenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-fenylbutan-1-on
29		(S)-1-(5-(benzo[d]tiazol-6-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)yl)-3-hydroksy-2-fenylpropan-1-on
31		(S)-1-(5-((4-(difluormetoksy)fenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-fenylpropan-1-on

37		1-(5-((3,4-dihydro-2H-benzo[b][1,4]oksazin-6-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2,2-dimetylpropan-1-on
41		(S)-1-(5-((4-(difluormetoksy)fenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-(pyridin-2-yl)propan-1-on
48		1-(5-(benzo[d]tiazol-6-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-fenylpropan-1-on
49		1-(5-((4-(difluormetoksy)fenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-fenylpropan-1-on
51		(2S)-3-hydroksy-2-fenyl-1-[5-(pyridin-2-sulfonyl)-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl]propan-1-on

eller et farmasøytisk akseptabelt salt derav.

2. Forbindelse ifølge krav 1, hvor forbindelsen er (S)-1-(5-((2,3-dihydro-[1,4]dioksino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-fenylpropan-1-on eller et farmasøytisk akseptabelt salt derav.

5

3. Forbindelse ifølge krav 1, hvor forbindelsen er (R)-1-(5-((2,3-dihydro-[1,4]dioksino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-(pyridin-2-yl)propan-1-on eller et farmasøytisk akseptabelt salt derav.

10

4. Forbindelse ifølge krav 1, hvor forbindelsen er (2S,3R og 2R,3S)-1-(5-((4-(difluormetoksy)fenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-fenylbutan-1-on eller et farmasøytisk akseptabelt salt derav.
- 5 5. Forbindelse ifølge krav 1, hvor forbindelsen er (2R,3R og 2S,3S)-1-(5-((4-(difluormetoksy)fenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-fenylbutan-1-on eller et farmasøytisk akseptabelt salt derav.
6. Forbindelse ifølge krav 1, hvor forbindelsen er (S)-1-(5-(benzo[d]tiazol-6-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)yl)-3-hydroksy-2-fenylpropan-1-on eller et farmasøytisk akseptabelt salt derav.
- 10
7. Forbindelse ifølge krav 1, hvor forbindelsen er (S)-1-(5-((4-(difluormetoksy)fenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-fenylpropan-1-on eller et farmasøytisk akseptabelt salt derav.
- 15
8. Forbindelse ifølge krav 1, hvor forbindelsen er 1-(5-((3,4-dihydro-2H-benzo[b][1,4]oksazin-6-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2,2-dimetylpropan-1-on eller et farmasøytisk akseptabelt salt derav.
- 20
9. Forbindelse ifølge krav 1, hvor forbindelsen er (S)-1-(5-((4-(difluormetoksy)fenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-(pyridin-2-yl)propan-1-on eller et farmasøytisk akseptabelt salt derav.
- 25
10. Forbindelse ifølge krav 1, hvor forbindelsen er 1-(5-(benzo[d]tiazol-6-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-fenylpropan-1-on eller et farmasøytisk akseptabelt salt derav.
- 30
11. Forbindelse ifølge krav 1, hvor forbindelsen er 1-(5-((4-(difluormetoksy)fenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroksy-2-fenylpropan-1-on eller et farmasøytisk akseptabelt salt derav.
- 35
12. Forbindelse ifølge krav 1, hvor forbindelsen er (2S)-3-hydroksy-2-fenyl-1-[5-(pyridin-2-sulfonyl)-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl]propan-1-on eller et farmasøytisk akseptabelt salt derav.

13. Farmasøytisk sammensetning, omfattende en forbindelse ifølge et hvilket som helst av kravene 1-12 eller et farmasøytisk akseptabelt salt derav, og en farmasøytisk akseptabel bærer.